表1.

所有患者临床病理学特征（n=159）

Characteristic	n (%)
Age, median (range)(yr) <65 ≥65	64 (32-86) 85 (53.5) 74 (46.5)
Gender Male Female	62 (39.0) 97 (61.0)
Smoking history Never Current or former	112 (70.4) 47 (29.6)
Pathologic type Adenocarcinoma Squamous-cell carcinoma Adenosquamous carcinoma	151 (95.0) 4 (2.5) 4 (2.5)
PD-L1 expression (TPS) TPS<1% 1%≤TPS<50% TPS≥50%	75 (47.2) 51 (32.1) 33 (20.7)
Primary EGFR mutation 19del L858R Others	76 (47.8) 65 (40.9) 18 (11.3)
CEA level (>6 ng/mL) Normal Elevated	59 (37.1) 100 (62.9)
TP53 comutation Yes No Unknown	37 (34.6) 70 (65.4) 52 (32.9)
Morphology of cancer cell Acinar predominant Papillary/Micropapillary predominant Solid predominant Unknown	75 (47.2) 33 (20.8) 34 (21.4) 17 (10.6)
Brain metastasis Yes No	31 (19.5) 128 (80.5)
Treatment EGFR-TKIs monotherapy EGFR-TKIs combination therapy	124 (78.0) 35 (22.0)
Radiotherapy Yes No	22 (15.6) 137 (86.2)
RECIST response PD SD PR	8 (5.0) 68 (42.8) 83 (52.2)

PD-L1: programmed cell death ligand 1; TPS: tumor proportion score; CEA: carcinoembryonic antigen; TP53: tumor protein p53; EGFR-TKIs: epidermal growth factor receptor tyrosine kinase inhibitors; RECIST: Response Evaluation Criteria in Solid Tumors; PD: progressive disease; SD: stable disease; PR: partial response; 19del: exon 19 deletion; L858R: 21 exon L858R mutation.